Cargando…

Exploring Anti-Type 2 Diabetes Mellitus Mechanism of Gegen Qinlian Decoction by Network Pharmacology and Experimental Validation

PURPOSE: Gegen Qinlian Decoction (GGQL) has been employed to treat type 2 diabetes mellitus (T2DM) in the clinical practice of traditional Chinese medicine. However, the underlying mechanism of GGQL in the treatment of T2DM remains unknown. This study was aimed at exploring the pharmacological mecha...

Descripción completa

Detalles Bibliográficos
Autores principales: Bao, Weiping, Sun, Hongping, Wu, Xiang, Xu, Juan, Zhang, Huifeng, Cao, Lin, Fan, Yaofu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588339/
https://www.ncbi.nlm.nih.gov/pubmed/36284987
http://dx.doi.org/10.1155/2022/1927688
_version_ 1784814109867376640
author Bao, Weiping
Sun, Hongping
Wu, Xiang
Xu, Juan
Zhang, Huifeng
Cao, Lin
Fan, Yaofu
author_facet Bao, Weiping
Sun, Hongping
Wu, Xiang
Xu, Juan
Zhang, Huifeng
Cao, Lin
Fan, Yaofu
author_sort Bao, Weiping
collection PubMed
description PURPOSE: Gegen Qinlian Decoction (GGQL) has been employed to treat type 2 diabetes mellitus (T2DM) in the clinical practice of traditional Chinese medicine. However, the underlying mechanism of GGQL in the treatment of T2DM remains unknown. This study was aimed at exploring the pharmacological mechanisms of GGQL against T2DM via network pharmacology analysis combined with experimental validation. METHODS: The effective components of GGQL were screened, and the target was predicted by using traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP). The candidate targets of GGQL were predicted by network pharmacological analysis, and crucial targets were chosen by the protein-protein interaction (PPI) network. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analyses were performed to predict the core targets and pathways of GGQL against T2DM. Then, T2DM mice were induced by a high-fat diet combined with streptozotocin. The model and GGQL groups were given normal saline and GGQL aqueous solution (10 and 20 g/kg/d) intragastric administration, respectively, for 8 weeks. The mice in the GGQLT groups were administered with GGQLT at 10 and 20 g/kg/d, respectively. The pathological changes in liver tissues were observed by hematoxylin-eosin staining. The protein expression of TNF-α and NF-κB was verified by western blotting. RESULTS: A total of 204 common targets of GGQL for the treatment of T2DM were obtained from 140 active ingredients and 212 potential targets of T2DM. GO and KEGG enrichment analysis involved 119 signaling pathways, mainly in inflammatory TNF signaling pathways. Animal experiments showed that GGQL significantly reduced the serum levels of body mass, fasting blood glucose, fasting insulin, HOMA-IR, TNF-α, and IL-17. The liver pathological section showed that GGQL could improve the vacuolar degeneration and lipid deposition in the liver of T2DM mice. Mechanistically, GGQL downregulated the mRNA expression of TNF-α and NF-κB. CONCLUSIONS: This study demonstrated that GGQL may exert antidiabetic effects against T2DM by suppressing TNF-α signaling pathway activation, thus providing a basis for its potential use in clinical practice and further study in treating T2DM.
format Online
Article
Text
id pubmed-9588339
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-95883392022-10-24 Exploring Anti-Type 2 Diabetes Mellitus Mechanism of Gegen Qinlian Decoction by Network Pharmacology and Experimental Validation Bao, Weiping Sun, Hongping Wu, Xiang Xu, Juan Zhang, Huifeng Cao, Lin Fan, Yaofu Dis Markers Research Article PURPOSE: Gegen Qinlian Decoction (GGQL) has been employed to treat type 2 diabetes mellitus (T2DM) in the clinical practice of traditional Chinese medicine. However, the underlying mechanism of GGQL in the treatment of T2DM remains unknown. This study was aimed at exploring the pharmacological mechanisms of GGQL against T2DM via network pharmacology analysis combined with experimental validation. METHODS: The effective components of GGQL were screened, and the target was predicted by using traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP). The candidate targets of GGQL were predicted by network pharmacological analysis, and crucial targets were chosen by the protein-protein interaction (PPI) network. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analyses were performed to predict the core targets and pathways of GGQL against T2DM. Then, T2DM mice were induced by a high-fat diet combined with streptozotocin. The model and GGQL groups were given normal saline and GGQL aqueous solution (10 and 20 g/kg/d) intragastric administration, respectively, for 8 weeks. The mice in the GGQLT groups were administered with GGQLT at 10 and 20 g/kg/d, respectively. The pathological changes in liver tissues were observed by hematoxylin-eosin staining. The protein expression of TNF-α and NF-κB was verified by western blotting. RESULTS: A total of 204 common targets of GGQL for the treatment of T2DM were obtained from 140 active ingredients and 212 potential targets of T2DM. GO and KEGG enrichment analysis involved 119 signaling pathways, mainly in inflammatory TNF signaling pathways. Animal experiments showed that GGQL significantly reduced the serum levels of body mass, fasting blood glucose, fasting insulin, HOMA-IR, TNF-α, and IL-17. The liver pathological section showed that GGQL could improve the vacuolar degeneration and lipid deposition in the liver of T2DM mice. Mechanistically, GGQL downregulated the mRNA expression of TNF-α and NF-κB. CONCLUSIONS: This study demonstrated that GGQL may exert antidiabetic effects against T2DM by suppressing TNF-α signaling pathway activation, thus providing a basis for its potential use in clinical practice and further study in treating T2DM. Hindawi 2022-10-15 /pmc/articles/PMC9588339/ /pubmed/36284987 http://dx.doi.org/10.1155/2022/1927688 Text en Copyright © 2022 Weiping Bao et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Bao, Weiping
Sun, Hongping
Wu, Xiang
Xu, Juan
Zhang, Huifeng
Cao, Lin
Fan, Yaofu
Exploring Anti-Type 2 Diabetes Mellitus Mechanism of Gegen Qinlian Decoction by Network Pharmacology and Experimental Validation
title Exploring Anti-Type 2 Diabetes Mellitus Mechanism of Gegen Qinlian Decoction by Network Pharmacology and Experimental Validation
title_full Exploring Anti-Type 2 Diabetes Mellitus Mechanism of Gegen Qinlian Decoction by Network Pharmacology and Experimental Validation
title_fullStr Exploring Anti-Type 2 Diabetes Mellitus Mechanism of Gegen Qinlian Decoction by Network Pharmacology and Experimental Validation
title_full_unstemmed Exploring Anti-Type 2 Diabetes Mellitus Mechanism of Gegen Qinlian Decoction by Network Pharmacology and Experimental Validation
title_short Exploring Anti-Type 2 Diabetes Mellitus Mechanism of Gegen Qinlian Decoction by Network Pharmacology and Experimental Validation
title_sort exploring anti-type 2 diabetes mellitus mechanism of gegen qinlian decoction by network pharmacology and experimental validation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588339/
https://www.ncbi.nlm.nih.gov/pubmed/36284987
http://dx.doi.org/10.1155/2022/1927688
work_keys_str_mv AT baoweiping exploringantitype2diabetesmellitusmechanismofgegenqinliandecoctionbynetworkpharmacologyandexperimentalvalidation
AT sunhongping exploringantitype2diabetesmellitusmechanismofgegenqinliandecoctionbynetworkpharmacologyandexperimentalvalidation
AT wuxiang exploringantitype2diabetesmellitusmechanismofgegenqinliandecoctionbynetworkpharmacologyandexperimentalvalidation
AT xujuan exploringantitype2diabetesmellitusmechanismofgegenqinliandecoctionbynetworkpharmacologyandexperimentalvalidation
AT zhanghuifeng exploringantitype2diabetesmellitusmechanismofgegenqinliandecoctionbynetworkpharmacologyandexperimentalvalidation
AT caolin exploringantitype2diabetesmellitusmechanismofgegenqinliandecoctionbynetworkpharmacologyandexperimentalvalidation
AT fanyaofu exploringantitype2diabetesmellitusmechanismofgegenqinliandecoctionbynetworkpharmacologyandexperimentalvalidation